Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194985 | 0.90 | NPC1 (0.40) | ALOX5NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7193872 | 0.89 | ALOX5 (0.39) | ALOX5NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7198585 | 0.89 | NPC1 (0.45) | ALOX5NPC1PKMRAB9ATDP1 | |
| SCHEMBL7194731 | 0.88 | PPARG (0.36) | NPC1PKMRAB9ATDP1L3MBTL1 | |
| SCHEMBL7194222 | 0.85 | ALOX5 (0.38) | ALOX5NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7189750 | 0.84 | ALOX5 (0.40) | ALOX5NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7192510 | 0.83 | TAS1R3 (0.42) | ALOX5NPC1PKMRAB9ATDP1 | |
| SCHEMBL7189684 | 0.82 | PPARG (0.42) | NPC1PKMRAB9APPARGPPARD | |
| SCHEMBL7189707 | 0.80 | ALOX5 (0.43) | ALOX5NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7196714 | 0.80 | NPC1 (0.42) | ALOX5NPC1PKMRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | ALOX5 1298/4885NPC1 3105/4885PKM 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.